- Teens With Epilepsy Face Higher Odds for Eating Disorders
- Head Injury Left Her Memory-Impaired. A New Brain Implant Has Brought Memory Back
- Flu, COVID Cases Climb as RSV Infections Start to Level Off
- STD Specialists Warn of Shortage of Vital Syphilis Drug
- Do You Overindulge During the Holidays? Poll Finds You’re Not Alone
- One Food Could Boost Health of Colon Cancer Survivors
- ‘High Altitude’ Simulations Might Shield Patients Ahead of Surgery
- Timing of Menopause Could Affect a Woman’s Muscle Loss
- Immediate Body Contact With Parents Helps Preemie Newborns Thrive
- Trim Your Holiday Stress This Season: Experts Offer Tips
Tretten Approved for Genetic Clotting Disorder

Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
People with the genetic disorder do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in yeast cells, makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.
Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.
The product was developed and is produced by Novo Nordisk, based in Denmark.
More information
To learn more about this disorder, visit the National Hemophilia Foundation.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.